Clinical trials
Follow clinical development from study design and recruitment through results.
- Trial phase
- Status
- Readouts
Drug intelligence / Profile preview
Remedril
- Development stage
- Phase 3
- Lead developer
- Remed Pharmaceuticals
- Modality
- Small Molecules
- Administration
- Oral
01
Overview
**Remedril** is an oral fixed-dose combination of phenylephrine hydrochloride and brompheniramine maleate marketed by Remed Pharmaceuticals for symptomatic management of upper-respiratory allergic and cold symptoms. Phenylephrine is a direct alpha-1 adrenergic receptor agonist that constricts nasal mucosal blood vessels to reduce congestion, while brompheniramine is a sedating first-generation histamine H1 receptor antagonist that reduces histamine-mediated sneezing, rhinorrhea, itching, and watery eyes. The product is supplied as syrup and oral drops and is indicated for common colds, allergic rhinitis, and sinusitis.
- Brand names
- Remedril
- Other names
- brompheniramine maleate + phenylephrine hydrochloridephenylephrine hydrochloride + brompheniramine maleate
02
Targets
HRH1 (Histamine H1 Receptor)ADRA1A (α1A)
Beyond the preview
Go deeper on Remedril.
Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.
Indications & development
Explore development by indication, patient population, and geography.
- Indications
- Development status
- Countries
Licensing & deals
Trace asset ownership, licensing agreements, and commercial partnerships.
- Partners
- Deal terms
- Milestones
Patents & exclusivity
Explore the patent landscape and regulatory exclusivity around an asset.
- Patents
- Expiration dates
- Exclusivity
Competitive landscape
Compare development programs by target, modality, and indication.
- Competing assets
- Targets
- Development stage
Research & analysis
Connect source evidence and development news to your research questions.
- Publications
- News
- Analysis
Bring the full picture into focus.
See how Gosset can support your research on Remedril.